United States biological products, excluding disgnostic substances industry landscape illustrating listed-company operations, infrastructure and market activity

Prism Finance USA · comparison snapshot

Biological Products, Excluding Disgnostic Substances Stocks in USA: Revenue Cohort 7

Name: Biological Products, Excluding Disgnostic Substances Stocks in USA: Revenue Cohort 7 comparison snapshot
Creator: Fliar BI Prism

A five-company biological products, excluding disgnostic substances cohort selected by latest filing revenue, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 28 August 2026Not investment adviceRanked by Prism readiness

Readiness leaderPrecision BioSciences · 47

Strongest available pathKymeratx · +93.5%

Widest latest marginPrecision BioSciences · -133.4%

Companies compared5 · U.S.-listed

01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1DTIL · Nasdaq

Precision BioSciences

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2006Durham, North Carolina$214.7M market cap

View full Companies Radar profile

47Cautious

Snapshot price$7.78as of page date

Monthly-close return-97.8%five-year window

FY2025 revenue$0.03BPRECISION BIOSCIENCES INC

Net margin-133.4%FY2025

P/E snapshot-4.2xone ratio, not a verdict

Prism attention30.1%share across these five

Filing track recordRevenue, USD billions

-70.3%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -26.2%

52-week position70% through range

$3.53$9.62

News mentions1.3K

Community mentions38partial coverage

U.S.-scope patents68

Prism InsightsWhat sits behind the readiness signal
Observed risk 4/100higher means more observed risk

Earnings signal59/100
Management stability90/100
Market position0/100
Capital-event signal80/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 1 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2XFOR · Nasdaq

Arsanis

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2014Boston, Massachusetts$400.6M market cap

View full Companies Radar profile

37Cautious

Snapshot price$4.04as of page date

Monthly-close return-97.3%five-year window

FY2025 revenue$0.04BX4 Pharmaceuticals, Inc

Net margin-225.6%FY2025

P/E snapshot2.8xone ratio, not a verdict

Prism attention16.2%share across these five

Filing track recordRevenue, USD billions

+903.2%

FY2018–FY2025 · 4 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 115.7%

52-week position61% through range

$2.80$4.83

News mentions704

Community mentions3partial coverage

U.S.-scope patents2

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal50/100
Management stability90/100
Market position3/100
Capital-event signal29/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3CCCC · Nasdaq

C4 Therapeutics

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2016Cambridge, Massachusetts$473.6M market cap

View full Companies Radar profile

34Cautious

Snapshot price$3.85as of page date

Monthly-close return-89.8%five-year window

FY2025 revenue$0.04BC4 Therapeutics, Inc.

Net margin-292.1%FY2025

P/E snapshot-3.9xone ratio, not a verdict

Prism attention17.5%share across these five

Filing track recordRevenue, USD billions

+15.6%

FY2022–FY2025 · 4 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 5.0%

52-week position62% through range

$1.69$5.17

News mentions758

Community mentions9partial coverage

U.S.-scope patents380

Prism InsightsWhat sits behind the readiness signal
Observed risk 4/100higher means more observed risk

Earnings signal32/100
Management stability90/100
Market position0/100
Capital-event signal47/100
Innovation pulse5/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 1 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4KYMR · Nasdaq

Kymeratx

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2016Cambridge, Massachusetts$9.82B market cap

View full Companies Radar profile

33Cautious

Snapshot price$118.2as of page date

Monthly-close return+93.5%five-year window

FY2025 revenue$0.04BKymera Therapeutics, Inc.

Net margin-794.0%FY2025

P/E snapshot-24.0xone ratio, not a verdict

Prism attention11.1%share across these five

Filing track recordRevenue, USD billions

-46.2%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -14.3%

52-week position87% through range

$39.84$130.1

News mentions481

Community mentions0partial coverage

U.S.-scope patents0

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal26/100
Management stability90/100
Market position0/100
Capital-event signal46/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 1 key-person event recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5VYGR · Nasdaq

Voyager Therapeutics

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2014Cambridge, Massachusetts$218.1M market cap

View full Companies Radar profile

31Cautious

Snapshot price$3.54as of page date

Monthly-close return+6.1%five-year window

FY2025 revenue$0.04BVoyager Therapeutics, Inc.

Net margin-296.5%FY2025

P/E snapshot-2.8xone ratio, not a verdict

Prism attention25.1%share across these five

Filing track recordRevenue, USD billions

+7.9%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 1.9%

52-week position23% through range

$2.94$5.55

News mentions1.1K

Community mentions10partial coverage

U.S.-scope patents791

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal32/100
Management stability90/100
Market position0/100
Capital-event signal25/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 16 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Kymeratx

+93.5%

Voyager Therapeutics

+6.1%

C4 Therapeutics

-89.8%

Arsanis

-97.3%

Precision BioSciences

-97.8%

Latest revenue

USD billions, official filing scope shown on each company card.

Voyager Therapeutics

$0.04B

Kymeratx

$0.04B

C4 Therapeutics

$0.04B

Arsanis

$0.04B

Precision BioSciences

$0.03B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Precision BioSciences

-133.4%

Arsanis

-225.6%

C4 Therapeutics

-292.1%

Voyager Therapeutics

-296.5%

Kymeratx

-794.0%

Prism news attention

Normalized share across these five names; attention is not quality.

Precision BioSciences

30.1%

Voyager Therapeutics

25.1%

C4 Therapeutics

17.5%

Arsanis

16.2%

Kymeratx

11.1%

03 · Prism readout

What the signals say—and what they do not

The headline share is normalized biological products, excluding disgnostic substances news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Precision BioSciences leads the conversation

It holds 30.1% of measured biological products, excluding disgnostic substances news attention and also carries the basket's largest revenue base at $0.03B.

Price path

Kymeratx leads the available price paths

Its monthly-close return is +93.5% for the five-year window. At the other end, Precision BioSciences is -97.8% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Precision BioSciences has the widest latest margin

Its FY2025 net margin is -133.4%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Kymeratx shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -24.0x while its five-year window price return is +93.5%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · DTIL

Precision BioSciences

1,311available Prism news records

Prism top themes

Legal, arbitration & regulatory

Leadership & governance

Price action & investor response

Earnings & financial performance

Capital allocation & transactions

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+6.7%191 latest 12m vs 179 prior 12m

Machine-classified coverage tone

94.3% positive+0.5 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

gene therapy rare diseases 72crispr-cas9 43crispr applications 37synthetic biology 27gene knockout 22gene delivery systems 20therapeutic genome editing 19diagnostic biotechnology 18

Keyword tag occurrences in available Prism news records.

Coverage: 2010-09-07–2026-06-09 · trend and themes shown through 2026-06

Areas of research · VYGR

Voyager Therapeutics

1,088available Prism news records

Prism top themes

Price action & investor response

Capital allocation & transactions

Legal, arbitration & regulatory

Leadership & governance

Earnings & financial performance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-36.8%98 latest 12m vs 155 prior 12m

Machine-classified coverage tone

92.6% positive+4.7 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

gene therapy rare diseases 54gene delivery systems 14stock performance 12tau phosphorylation 11share price 10stem cell banking 9orphan drug pricing 8startup valuation 7

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-06-13 · trend and themes shown through 2026-06

05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

DTIL

Precision BioSciences

38 mentions

Stock and valuation

Products, pricing and logistics

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 38 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

DTIL

Precision BioSciences

through 2025-12-23

Earnings releases 8Company announcements 3Leadership changes 2Business contracts 1Regulatory 1

2025-12-23
Regulatory
the Compensation Committee of Precision’s Board of Directors approved the grant of an inducement award of 8,224 restricted stock units ("RSUs") to a new employee under the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan ("Inducement Award Plan") in connection with their commencement of employment.
2025-03-26
Earnings releases
Precision BioSciences Inc. (DTIL) on Wednesday reported a loss of \$17.7 million in its fourth quarter.
2024-05-08
Business contracts
Precision BioSciences, Inc. (Nasdaq: DTIL) (the “Company”), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, elimination, and excision, today announced that it has entered into a definitive subscription agreement, pursuant to which the Company will issue and sell in a non-brokered private placement to members of its senior leadership team, including the Chief Executive Officer, 25,000 shares of its common stock at a price of $12.00 per share, representing a 13.5% premium to the closing price of its common stock immediately preceding the signing of the subscription agreement, for an aggregate amount of $300,000 (the “Private Placement”).

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

XFOR

Arsanis

through 2025-02-14

Listing / IPO 1

2025-02-14
Listing / IPO
Arsanis Inc., a Waltham, Mass.-based company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, saw its shares (NASDAQ:ASNS) rise 40.3 percent to close at $14.03 on Thursday, its first trading day after an IPO of 4 million shares priced at $10 per share. The IPO price was significantly below the initial $15 to $17 per share range in which the company had hoped to price. Gross proceeds were expected to be $40 million.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

CCCC

C4 Therapeutics

through 2026-01-26

Leadership changes 4Earnings releases 1Regulatory 1

2026-01-26
Regulatory
C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase 85,480 shares of the Company’s common stock to one new employee (the “Inducement Grant”), with the grant made on January 26, 2026 (the “Grant Date”).
2024-11-21
Leadership changes
C4 Therapeutics added Steve Hoerter to the board of directors.
2023-08-08
Earnings releases
Revenue: Total revenue for the second quarter of 2023 was $2.7 million, compared to $13.8 million for the second quarter of 2022. Net loss for the second quarter of 2023 was $35.9 million, compared to $27.4 million for the second quarter of 2022.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

KYMR

Kymeratx

through 2026-02-26

Earnings releases 12Listing / IPO 4Leadership changes 3

2026-02-26
Earnings releases
Collaboration revenues were 2.9 million for the fourth quarter of 2025 and 39.2 million for the year ended December 31, 2025 compared to 7.4 million and 47.1 million, respectively, for the same periods of 2024.
2025-12-10
Listing / IPO
Kymera Therapeutics, Inc. (NASDAQ: KYMR) today announced the pricing of its underwritten public offering of $602.0 million of shares of its common stock.
2025-09-10
Leadership changes
Similarly, biopharmaceutical company Kymera Therapeutics has named Brian Adams as chief legal officer and corporate secretary.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

VYGR

Voyager Therapeutics

through 2026-01-05

Earnings releases 10Business contracts 9Leadership changes 3Listing / IPO 2

2026-01-05
Earnings releases
Based on Voyager Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $13.37 million and a GAAP net loss of $27.89 million.
2025-02-14
Listing / IPO
Voyager Therapeutics Inc., of Cambridge, Mass., has set terms for its IPO and is planning to raise up to $86.3 million by offering approximately 4.69 million shares in the price range of $15 to $17 per share.
2025-02-14
Leadership changes
Voyager Therapeutics Inc., of Cambridge, Mass., named Robert G. Pietrusko senior vice president of regulatory affairs.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Biological Products, Excluding Disgnostic Substances Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary biological products, excluding disgnostic substances news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

biologics market

26 sources67.0% extraction confidence

2020 extracted base$194.20B–$477.15B

2033 extracted forecast$685.30B–$1.37T

Implied source CAGR8.5%

high demand for the treatment of different disease indicationsTechnologyadvancements in biotechnology

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, Asia Pacific, North America, Mexico. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Biological Products, Excluding Disgnostic Substances news pulse

24,998available Prism news records

Latest 12m volume+9.8%10786 vs 9825 records

Positive classified tone41.7%+4.6 pp vs prior four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Available U.S.-primary Prism records matching biological, disgnostic, excluding, substance, biologic. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

harm reduction strategies

4,078

substance abuse education

3,736

opioid addiction and treatment

3,643

overdose prevention techniques

3,482

controlled substance regulations

3,381

substance abuse overdose fatalities

3,287

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

mind-altering drug consumption 1,795opioid diversion abuse 1,702fentanyl treatment programs 1,649drug overdose 1,576psychedelic mental health studies 1,328cannabis policy reform discussions 1,328medication-assisted treatment opioids 1,265psychoactive drug intake 1,170

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

high demand for the treatment of different disease indications

26 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card

Opportunity · demand

harm reduction strategies

4,078 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata

Opportunity · innovation

Innovation and product activity

2,049 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule

Caution · market restraint

Biosimilars entering the market

1,542 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata

Caution · news pulse

Coverage growth can reverse

+9.8% news volume

The latest 12 months contain 10,786 matched records versus 9,825 in the previous window.

Available Prism coverage through 2026-05-05

Caution · sentiment

Classified tone is not demand

41.7% positive · +4.6pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →

08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2836 (Biological Products, Excluding Disgnostic Substances), selected as the first five names that pass all live publication gates from the latest filing revenue candidate pool ranked 31–38. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

Official annual filingsFY revenue history and latest profitability
U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
Prism market-growth extractionDated third-party Biological Products, Excluding Disgnostic Substances Industry in USA market benchmark with source-count, geography and confidence context

Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 28 August 2026.

09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

Precision BioSciences leads the readiness ranking

Its Prism readiness score is 47/100, the highest in this five-company comparison.

Open Precision BioSciences in Companies Radar

Scale and margin leadership sit with Voyager Therapeutics and Precision BioSciences

Voyager Therapeutics has the largest displayed latest revenue at $0.04B; Precision BioSciences has the widest displayed latest margin at -133.4%.

Open Voyager Therapeutics in Companies Radar Open Precision BioSciences in Companies Radar

Comparisons

Strongest versus weakest available price path

Kymeratx is +93.5% for its five-year window; Precision BioSciences is -97.8% for its five-year window.

Open Kymeratx in Companies Radar Open Precision BioSciences in Companies Radar

Largest versus smallest displayed revenue base

The latest displayed revenue ranges from $0.04B for Voyager Therapeutics to $0.03B for Precision BioSciences. Entity and filing-period labels remain visible on the company cards.

Open Voyager Therapeutics in Companies Radar Open Precision BioSciences in Companies Radar

Anomalies

Voyager Therapeutics has the widest attention-readiness rank gap

It ranks #2 by measured news attention (25.1%) and #5 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Voyager Therapeutics in Companies Radar

Arsanis shows a price-operating divergence to inspect

Its displayed filing-revenue change is +903.2% while its available monthly-close return is -97.3%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Arsanis in Companies Radar

Explanations

Attention measures coverage volume, not quality

Precision BioSciences's 30.1% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Precision BioSciences in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Precision BioSciences's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 47/100 score.

Open Precision BioSciences in Companies Radar

Stress-test the largest divergence before forming a view

Compare Arsanis's profile with Kymeratx's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open Arsanis in Companies Radar Open Kymeratx in Companies Radar

Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.